科研之友
微信
新浪微博
Facebook
分享链接
摘要
Efforts to understand and harness the potent anti-inflammatory and immunomodulating properties of the endogenous lipid mediators lipoxin A(4) (LXA(4)), lipoxin B-4 (LXB4) and the aspirin-triggered lipoxins, have resulted in a number of patent applications by both academic research groups and pharmaceutical companies. The patents cover the anti-inflammatory properties of lipoxins across a range of diseases with components of inflammation.
- 出版日期2007-6
